Literature DB >> 25547253

Effect of prior hemorrhage on intracranial arteriovenous malformation radiosurgery outcomes.

Dale Ding1, Chun-Po Yen, Robert M Starke, Zhiyuan Xu, Jason P Sheehan.   

Abstract

BACKGROUND: Intracerebral hemorrhage is simultaneously the most frequent and most debilitating manifestation of intracranial arteriovenous malformations (AVM), but its impact on success and complications of radiosurgery has not been rigorously assessed. In this case-control study, we define the effect of prior hemorrhage on AVM radiosurgery outcomes.
METHODS: From a prospective, institutional database of 1,400 AVM patients treated with Gamma Knife radiosurgery, unruptured and ruptured AVMs were matched in a 1:1 fashion, blinded to outcome, based on patient demographics, prior embolization (26.6% of each cohort), AVM size (mean volume of unruptured AVMs 3.7 cm(3) versus ruptured AVMs 3.5 cm(3), p = 0.195), Spetzler-Martin grade (Grade I 17.0%, Grade II 37.8%, Grade III 34.8%, Grade IV 10.4% for each cohort), and radiosurgical treatment parameters (mean prescription dose for unruptured AVMs 20.9 Gy versus ruptured AVMs 21.0 Gy, p = 0.837). There were 270 patients in each cohort. Matched statistical analyses were used to compare the baseline characteristics, obliteration rates, post-radiosurgery latency period hemorrhage risks, and incidences of radiation-induced changes (RIC) between the two cohorts.
RESULTS: The actuarial obliteration rates of the two cohorts were similar (unruptured AVMs: 38, 58, and 76% at 3, 5, 10 years, respectively; ruptured AVMs: 40, 60, and 73% at 3, 5, 10 years, respectively; p = 0.592). However, for embolized AVMs, complete obliteration was more likely to be achieved in unruptured lesions (unruptured AVMs: 25, 32, and 54% at 3, 5, 10 years, respectively; ruptured AVMs: 18, 27, and 42% at 3, 5, 10 years, respectively; p = 0.038). Prior AVM rupture resulted in a higher annual risk of post-radiosurgery latency period hemorrhage (ruptured AVMs 2.3% versus unruptured AVMs 1.1%, p = 0.025) but a lower rate of cumulative and symptomatic RIC (cumulative RIC: ruptured AVMs 30.4% versus unruptured AVMs 48.9%, p < 0.0001; symptomatic RIC: ruptured AVMs 7.0% versus unruptured AVMs 12.2%, p = 0.041, respectively). The rates of permanent RIC were similar between the unruptured (2.2%) and ruptured (1.9%) AVM cohorts (p = 0.761). The mean time interval to onset of RIC (unruptured AVMs 13.3 months versus ruptured AVMs 12.1 months, p = 0.783), and the mean duration of RIC (unruptured AVMs 22.0 months versus ruptured AVMs 21.7 months, p = 0.599) were not significantly different between the two cohorts.
CONCLUSIONS: Prior AVM rupture significantly alters the risk of latency period hemorrhage and RIC following radiosurgery. These effects should be taken into consideration with the multidisciplinary management of AVM patients. Radiosurgery does not significantly alter the natural history of the hemorrhage risks of unruptured and ruptured AVMs unless obliteration is achieved.
© 2014 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2014        PMID: 25547253     DOI: 10.1159/000369959

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  8 in total

1.  Management of brain arteriovenous malformations.

Authors:  Sherri A Braksick; Jennifer E Fugate
Journal:  Curr Treat Options Neurol       Date:  2015-07       Impact factor: 3.598

2.  Surgical Approaches for Symptomatic Cerebral Cavernous Malformations of the Thalamus and Brainstem.

Authors:  Dale Ding; Robert M Starke; R Webster Crowley; Kenneth C Liu
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2017-03-31

3.  Morbidity after Hemorrhage in Children with Untreated Brain Arteriovenous Malformation.

Authors:  Li Ma; Helen Kim; Xiao-Lin Chen; Chun-Xue Wu; Jun Ma; Hua Su; Yuanli Zhao
Journal:  Cerebrovasc Dis       Date:  2017-02-28       Impact factor: 2.762

4.  Stereotactic radiosurgery for ruptured versus unruptured intracranial arteriovenous malformations.

Authors:  James Mooney; Arsalaan Salehani; Nicholas Erickson; Evan Thomas; Adeel Ilyas; Sage Rahm; Nicholas Eustace; Pedram Maleknia; Omer Yousuf; Markus Bredel; John Fiveash; Chris Dobelbower; Winfield Fisher
Journal:  Surg Neurol Int       Date:  2022-05-06

5.  Stereotactic radiosurgery with versus without prior Onyx embolization for brain arteriovenous malformations.

Authors:  Ching-Jen Chen; Dale Ding; Cheng-Chia Lee; Kathryn N Kearns; I Jonathan Pomeraniec; Christopher P Cifarelli; David E Arsanious; Roman Liscak; Jaromir Hanuska; Brian J Williams; Mehran B Yusuf; Shiao Y Woo; Natasha Ironside; Rebecca M Burke; Ronald E Warnick; Daniel M Trifiletti; David Mathieu; Monica Mureb; Carolina Benjamin; Douglas Kondziolka; Caleb E Feliciano; Rafael Rodriguez-Mercado; Kevin M Cockroft; Scott Simon; Heath B Mackley; Samer G Zammar; Neel T Patel; Varun Padmanaban; Nathan Beatson; Anissa Saylany; John Y K Lee; Jason P Sheehan
Journal:  J Neurosurg       Date:  2020-12-11       Impact factor: 5.408

6.  Preoperative Embolization of Cerebral Arteriovenous Malformations with Silk Suture and Particles: Technical Considerations and Outcomes.

Authors:  Jordan R Conger; Dale Ding; Daniel M Raper; Robert M Starke; Christopher R Durst; Kenneth C Liu; Mary E Jensen; Avery J Evans
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2016-06-30

7.  Predictive Factors of Radiation-Induced Changes Following Single-Session Gamma Knife Radiosurgery for Arteriovenous Malformations.

Authors:  Myung Ji Kim; Kyung Won Chang; So Hee Park; Won Seok Chang; Jong Hee Chang; Jin Woo Chang; Hyun Ho Jung
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

8.  Comparison of the Long-term Efficacy and Safety of Gamma Knife Radiosurgery for Arteriovenous Malformations in Pediatric and Adult Patients.

Authors:  Hirotaka Hasegawa; Shunya Hanakita; Masahiro Shin; Mariko Kawashima; Wataru Takahashi; Osamu Ishikawa; Satoshi Koizumi; Hirofumi Nakatomi; Nobuhito Saito
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-05-17       Impact factor: 1.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.